MYHERITAGE
5.1.2021 14:02:16 CET | Business Wire | Press release
MyHeritage, the leading global platform for discovering your past and empowering your future, announced today that it is sponsoring a racing team in the 2021 Dakar Rally — the elite off-road endurance competition currently taking place in Saudi Arabia. The MyHeritage team comprises driver Danny Pearl, a veteran of off-road racing, and navigator Charly Gotlib, who has participated in the Dakar Rally more than 30 times over the years, and has received an honorary distinction of Dakar Legend from the race organizers. The team is managed by Omer Pearl, Danny’s son. In recent years, Omer has managed the Pearl Racing Team in different competitions around the world. The team is named the MyHeritage Team and is competing in the Dakar’s Lightweight Vehicle category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005542/en/
As the international market leader for exploring family history and finding relatives, MyHeritage develops innovative search and matching technologies and has a global database of historical records to help millions of people connect to their family history. Sponsoring a team led by a father-son duo is par for the course for MyHeritage. The company has a long history of partnering with top athletes, sports teams, and cultural figures to reveal their family history, forge connections with their relatives, and underscore the importance of knowing one’s roots.
Danny and Omer Pearl founded the Pearl Racing Team out of their passion for motorsports. The team has competed for many years in the SSV category, racing in numerous international competitions.
The Dakar Rally is considered the toughest and most grueling off-road competition in the world. This is the second year the competition is being held in Saudi Arabia, following its relocation from South America, where it was held for the last decade. The race spans more than 7,000 kilometers and 12 days over the challenging and beautiful Saudi terrain. This year’s race departed from Jeddah and will traverse the entire Arabian desert in a circular course. Each day the team will navigate under the most extreme conditions, using a Road Book produced by the rally organizer.
“As leaders in the field of exploring and discovering family history, we are thrilled to support a team that includes a father and son who are competing in one of the world’s most difficult competitions,” said Gilad Japhet, Founder and CEO of MyHeritage. “Particularly during these challenging times, we appreciate the significance of supporting family members coming together in bold and creative ways, working as a team to achieve the impossible. Just like the Dakar, family history can be an enjoyable and adventurous journey.”
“It is with great pride and excitement that we enter this legendary race,” said Omer Pearl. “We believe that determination and perseverance yield results, and our family bond is one of the driving forces behind our success. We hope that our efforts will inspire more families to team up and work together to pursue their dreams.”
The Dakar Rally is taking place between January 3–15, 2021.
About MyHeritage
MyHeritage is the leading global discovery platform for exploring family history. With billions of historical records and family tree profiles, and with sophisticated matching technologies that work across all its assets, MyHeritage allows users to discover their past and empower their future. Launched in 2016, MyHeritage DNA has become one of the world’s largest consumer DNA databases, with more than 4.6 million customers. Since 2020, MyHeritage is home to the world’s best technologies for enhancing and colorizing historical photos. MyHeritage is the most popular DNA test and family history service in Europe. www.myheritage.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom